Objective: To evaluate the therapeutic effect of tamoxifen monotherapy in patients with retroperitoneal fibrosis (RPF). Patients and Methods: From 2007 on, 31 patients with idiopathic RPF were treated with tamoxifen monotherapy. Follow-up investigations included magnetic resonance imaging, laboratory measurements, registration of side effects and changes or removal of ureteral stents. Data were stored in the Else Kröner-Fresenius Registry of Retroperitoneal Fibrosis. Results: 25 men and 6 women with a mean age of 56.6 years were treated with tamoxifen monotherapy. Mean duration of treatment was 13.3 months, mean follow-up 26.8 months. A total of 44 renal units were affected by hydronephrosis and covered by DJ stents. Radiological regression of fibrosis was detected in 22 cases (71.0%); removal of ureteral stents was possible in 27/44 renal units (61.4%) and 17/29 patients (58.6%), respectively. Most patients showed only mild or no side effects of therapy. In 7 cases (22.3%) tamoxifen therapy had to be abandoned because of severe side effects, progression of fibrosis or persistent intolerance. Conclusions: Tamoxifen is an alternative in the medical treatment of RPF, especially if patients want to avoid glucocorticoids. The potential of regression of fibrosis seems to be slightly inferior and the relapse rate is higher compared to steroids, but the rate of successful DJ removals is comparable.

Journal Section:
Editor's choice
Keywords:
Retroperitoneal fibrosis, Ormond’s disease, Tamoxifen
1.
Vaglio A, Salvarani C, Buzio C: Retroperitoneal fibrosis. Lancet 2006;367:241-251.
https://doi.org/10.1016/S0140-6736(06)68035-5
[PubMed]
2.
Kamper L, Brandt AS, Scharwachter C, Kukuk S, Roth S, Haage P, Piroth W: MR evaluation of retroperitoneal fibrosis. Rofo 2011;183:721-726.
[PubMed]
https://doi.org/10.1055/s-0031-1273450
3.
Brandt AS, Kamper L, Kukuk S, Haage P, Roth S: Associated findings and complications of retroperitoneal fibrosis in 204 patients: results of a urological registry. J Urol 2011;185:526-531.
[PubMed]
https://doi.org/10.1016/j.juro.2010.09.105
4.
Swartz RD: Idiopathic retroperitoneal fibrosis: a review of the pathogenesis and approaches to treatment. Am J Kidney Dis 2009;54:546-553.
[PubMed]
https://doi.org/10.1053/j.ajkd.2009.04.019
5.
Vaglio A: Retroperitoneal fibrosis: new insights into clinical presentation and diagnosis. Medicine (Baltimore) 2009;88:208-210.
[PubMed]
https://doi.org/10.1097/MD.0b013e3181afc4d1
6.
Pipitone N, Vaglio A, Salvarani C: Retroperitoneal fibrosis. Best Pract Res Clin Rheumatol 2012;26:439-448.
[PubMed]
https://doi.org/10.1016/j.berh.2012.07.004
7.
van Bommel EF, Jansen I, Hendriksz TR, Aarnoudse AL: Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore) 2009;88:193-201.
[PubMed]
https://doi.org/10.1097/MD.0b013e3181afc420
8.
Ilie CP, Pemberton RJ, Tolley DA: Idiopathic retroperitoneal fibrosis: the case for nonsurgical treatment. BJU Int 2006;98:137-140.
[PubMed]
https://doi.org/10.1111/j.1464-410X.2006.06210.x
9.
Heidenreich A, Derakhshani P, Neubauer S, Krug B: Treatment outcomes in primary and secondary retroperitoneal fibrosis (in German). Urologe A 2000;39:141-148.
[PubMed]
https://doi.org/10.1007/s001200050022
10.
van Bommel EF, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR: Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis 2007;49:615-625.
[PubMed]
https://doi.org/10.1053/j.ajkd.2007.02.268
11.
Kardar AH, Kattan S, Lindstedt E, Hanash K: Steroid therapy for idiopathic retroperitoneal fibrosis: dose and duration. J Urol 2002;168:550-555.
[PubMed]
https://doi.org/10.1016/S0022-5347(05)64677-0
12.
Fry AC, Singh S, Gunda SS, Boustead GB, Hanbury DC, McNicholas TA, Farrington K: Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: a retrospective study. Nephron Clin Pract 2008;108:c213-c220.
[PubMed]
https://doi.org/10.1159/000119715
13.
Li KP, Zhu J, Zhang JL, Huang F: Idiopathic retroperitoneal fibrosis (RPF): clinical features of 61 cases and literature review. Clin Rheumatol 2011;30:601-605.
[PubMed]
https://doi.org/10.1007/s10067-010-1580-6
14.
Marcolongo R, Tavolini IM, Laveder F, Busa M, Noventa F, Bassi P, Semenzato G: Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med 2004;116:194-197.
[PubMed]
https://doi.org/10.1016/j.amjmed.2003.08.033
15.
Alberici F, Palmisano A, Urban ML, Maritati F, Oliva E, Manenti L, Ferretti S, Cobelli R, Buzio C, Vaglio A: Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis 2013;72:1584-1586.
[PubMed]
https://doi.org/10.1136/annrheumdis-2013-203267
16.
Swartz RD, Lake AM, Roberts WW, Faerber GJ, Wolf JS Jr: Idiopathic retroperitoneal fibrosis: a role for mycophenolate mofetil. Clin Nephrol 2008;69:260-268.
[PubMed]
17.
Scheel PJ Jr, Piccini J, Rahman MH, Lawler L, Jarrett T: Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis. J Urol 2007;178:140-143; discussion 143-144.
[PubMed]
https://doi.org/10.1016/j.juro.2007.03.057
18.
Warnatz K, Keskin AG, Uhl M, Scholz C, Katzenwadel A, Vaith P, Peter HH, Walker UA: Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis 2005;64:828-833.
[PubMed]
https://doi.org/10.1136/ard.2004.029793
19.
Vaglio A, Palmisano A, Alberici F, Maggiore U, Ferretti S, Cobelli R, Ferrozzi F, Corradi D, Salvarani C, Buzio C: Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 2011;378:338-346.
[PubMed]
https://doi.org/10.1016/S0140-6736(11)60934-3
20.
van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG: Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 2006;144:101-106.
[PubMed]
https://doi.org/10.7326/0003-4819-144-2-200601170-00007
21.
van Bommel EF, Pelkmans LG, van Damme H, Hendriksz TR: Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis. Eur J Intern Med 2013;24:444-450.
[PubMed]
https://doi.org/10.1016/j.ejim.2012.11.010
22.
Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA: Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999;162:2003-2005.
[PubMed]
https://doi.org/10.1016/S0022-5347(05)68087-1
23.
Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP: The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992;70:648-651.
[PubMed]
https://doi.org/10.1111/j.1464-410X.1992.tb15836.x
24.
Kumar S, Sarkar D, Prasad S, Gupta V, Ghosala P, Kaman L, Yadav TD, Ganesamoni R, Singh SK: Large pelvic masses of obscure origin: urologist's perspective. Urol Int 2012;88:215-224.
[PubMed]
https://doi.org/10.1159/000334332
25.
Vaglio A, Greco P, Buzio C: Tamoxifen therapy for retroperitoneal fibrosis. Ann Intern Med 2006;144:619; author reply 619-620.
[PubMed]
https://doi.org/10.7326/0003-4819-144-8-200604180-00017
26.
Zen Y, Onodera M, Inoue D, Kitao A, Matsui O, Nohara T, Namiki M, Kasashima S, Kawashima A, Matsumoto Y, Katayanagi K, Murata T, Ishizawa S, Hosaka N, Kuriki K, Nakanuma Y: Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol 2009;33:1833-1839.
[PubMed]
https://doi.org/10.1097/PAS.0b013e3181b72882
27.
Yoshino T, Moriyama H, Fukushima M, Sanda N: A case of IgG4-related retroperitoneal fibrosis mimicking renal pelvic cancer. Urol Int 2013;90:365-368.
[PubMed]
https://doi.org/10.1159/000341703
28.
Marumo K, Tatsuno S, Noto K: Elevated serum IgG4 may predict sensitivity to steroid therapy in retroperitoneal fibrosis. Int J Urol 2009;16:427.
[PubMed]
https://doi.org/10.1111/j.1442-2042.2009.02255.x
29.
Magrey MN, Husni ME, Kushner I, Calabrese LH: Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Arthritis Rheum 2009;61:674-679.
[PubMed]
https://doi.org/10.1002/art.24461
30.
Pipitone N, Versari A, Vaglio A, Salvarani C: Role of 18F-fluorodeoxyglucose positron emission tomography in the workup of retroperitoneal fibrosis. Clin Exp Rheumatol 2011;29(1 suppl 64):S72-S78.
[PubMed]
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.